Analyst picks & changes

Genentech Inc.

Barbara Hoffman of Piper Jaffray said she wasn't impressed with results of Genentech Inc.'s Phase II trial of the anti-Her2 antibody

Read the full 225 word article

How to gain access

Continue reading with a
two-week free trial.